BioNexus Gene Lab (BGLC) Operating Expenses (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Operating Expenses data on file, last reported at $597386.0 in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 43.29% year-over-year to $597386.0; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (down 24.64% YoY), and the FY2025 full-year result was $4.5 million, down 9.18% from the prior year.
• Operating Expenses slipped to $597386.0 in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $6.2 million in Q3 2023 to a low of -$4.0 million in Q4 2023.
• A 5-year average of $1.0 million and a median of $1.1 million in 2025 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 662.26% in 2022 and slumped 506.52% in 2023, its largest moves.
• Tracing BGLC's Operating Expenses over 5 years: stood at $975716.0 in 2022, then tumbled by 506.52% to -$4.0 million in 2023, then jumped by 135.31% to $1.4 million in 2024, then fell by 24.86% to $1.1 million in 2025, then tumbled by 43.23% to $597386.0 in 2026.
• Business Quant data shows BGLC's Operating Expenses at $597386.0 in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.